The Latest Myeloma News from the American Society of Hematology Meeting

Published on

Loading the player...
Topics include: Treatments

Patient Power founder and host, Andrew Schorr, attended the 2007 American Society of Hematology annual meeting in Atlanta, Georgia, where more than 21,000 scientists and physicians came together to discuss and learn about new treatments and clinical trial results for patients with multiple myeloma. In this program, Andrew interviewed three of the leading experts in Multiple Myeloma: Dr. Brian Durie, Dr. James Berenson and Dr. Sagar Lonial. They each shared why they are excited about the news presented at the meeting and what the data means for patients.

On this episode, each expert brings their point-of-view on topics ranging from the latest information in clinical trials to combination therapies to the role of transplant and dietary supplementation in an aging population. Dr. Brian Durie, from the Cedars-Sinai Comprehensive Cancer Center in Los Angeles and medical director for the International Myeloma Foundation discusses the exciting news about combining novel agents Velcade, Revlimid, and thalidomide and the progress seen in frontline treatment with Revlimid and Dexamethasone combinations. Dr. Berenson, founder, president, and chief executive officer of the Institute for Myeloma and Bone Cancer Research, brings his perspectives on using Velcade with chemotherapeutic agents as well as his thoughts on maintaining a good quality of life for multiple myeloma patients. Dr. Sagar Lonial, from the Winship Comprehensive Cancer Center at Emory University, shares his thoughts on transplant and helps define the meaning of “CR” or Complete Remission and “VGPR” or Very Good Partial Remission.

As always, Andrew asked the questions that patients need answered so they can be their own best advocates and get the very best treatment available for their disease. In this program, the expert guests define how they approach determining the appropriate treatment for individual patients and outline all the various options offered so you can have a meaningful conversation with your doctor as you work out your course of therapy.

View more programs featuring , and


Andrew Schorr:

Hello, and thank you for joining us for another in our series of live web casts about multiple myeloma. I'm Andrew Schorr broadcasting live from Seattle, but I just got back as our guests have too from, I would say, a very exciting week in Atlanta. The temperature was great, and the temperature was high inside the Georgia World Congress Center as myeloma was very much on center stage.

There were five phase-III trials about multiple myeloma. There were poster sessions. There were over 21,000 scientists and physicians from around the world there, and many of them were focused on multiple myeloma. Maybe you saw, just even the other day, on the NBC Nightly News they focused on multiple myeloma and the story of a younger patient with multiple myeloma, and maybe that's why some of you are with us today.

So, we have the past programs we have done, and please look at those on under the special edition section, and two of those programs were with our guests today, and then we're going to add someone new. So, we have three expert physicians in multiple myeloma. We're going to get to as many questions as we can, but we want to explain the data that was presented in those studies and the relevant importance of each one. Could they mean longer survival? Could they mean time when maybe you don't need to take medicine? Could they mean changes in the medicines you take? If you're headed for a transplant, could there be different medicines to make that transplant more successful and maybe alleviate the need for a second transplant that some people have had? We're going to go through all that.

Let me tell you who some of our honored guests are today. We have with us again Dr. Brian Durie from Cedars-Sinai Comprehensive Cancer Center in Los Angeles, but beyond that Dr. Durie is the chairman of the board of the International Myeloma Foundation and its medical director. Brian, you and I have done programs over the years, and I know you're also I think co-chair of the myeloma group within the Southwestern Oncology clinical trials study group. Thank you so much for being with us again Brian.

Dr. Durie:

My pleasure to be with you again, Andrew.

Andrew Schorr:

Okay, and also across town there in Los Angeles is another myeloma expert who has been with us previously on Patient Power, and that's Dr. James Berenson. He is the Founder, President, and Chief Executive Officer of the Institute for Myeloma and Bone Cancer Research, and Jim, thank you for being with us again.

Dr. Berenson:

Thank you for having me this morning or afternoon, depending on where you are.

Andrew Schorr:

Where you are, that's right. Joining us shortly, if he's not with us yet, is we're going to go back to Atlanta and one of the doctors who didn't have to get on a plane is Dr. Sagar Lonial, and Dr. Lonial is at the Winship Comprehensive Cancer Center at Emory University. He is an assistant professor there, and he is Director of Translational Research B-Cell Malignancy Programs, and he certainly treats a lot of multiple myeloma and when appropriate helps people with transplant. So, lot's to talk about.

Dr. Durie, you got that title as Chairman, so we're probably going to start with you.

We will take some calls after we talk to the doctor, and you can e-mail our producers behind the scenes at One other point, I know right off the bat we will not get to everyone's questions today. We're going to cover what's important, so if we don't get to the area that you think we need to discuss, we will welcome your questions either now or in the next few days, and we're going to do a follow-up Q&A. Not a live webcast, but I'm going to interview him and record it with Dr. Tom Heffner, who's also from the Winship Comprehensive Cancer Center at Emory University in Atlanta, and then we'll post that a week from today. So, there's a lot going on, ample access to myeloma experts.

Related Programs

Multiple Myeloma Maintenance Therapy and Increased Survival

Dr. Maria-Victoria Mateos talks about a study from Spain revealing how lower doses of newer drugs can be used in the long-term to fight cancer with much lower side effects.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on November 22, 2013